Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease

INTRODUCTION: Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non‐steroidal anti‐inflammatory drug trials in AD and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Potter, Huntington, Woodcock, Jonathan H., Boyd, Timothy D., Coughlan, Christina M., O'Shaughnessy, John R., Borges, Manuel T., Thaker, Ashesh A., Raj, Balaibail A., Adamszuk, Katarzyna, Scott, David, Adame, Vanesa, Anton, Paige, Chial, Heidi J., Gray, Helen, Daniels, Joseph, Stocker, Michelle E., Sillau, Stefan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988877/
https://www.ncbi.nlm.nih.gov/pubmed/33778150
http://dx.doi.org/10.1002/trc2.12158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988877/
https://www.ncbi.nlm.nih.gov/pubmed/33778150
http://dx.doi.org/10.1002/trc2.12158

Ejemplares similares